Global Migraine Drugs Market 2016-2020 - Availability of Antimigraine Devices & Headbands - Research and Markets

News provided by

Research and Markets

20 May, 2016, 12:10 GMT

DUBLIN, May 20, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Migraine Drugs Market 2016-2020" report to their offering.

The report forecasts the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

One market trend to watch for is the development and availability of antimigraine devices and headbands. Antimigraine drugs are associated with various side effects and show less tolerance among the patients. Thus, the need for new treatment options has led to the development of various devices in the market. Antimigraine devices and headbands are being increasingly preferred for the prevention of migraines. The FDA has approved Cerena Transcranial Magnetic Stimulator and the Cefaly Transcutaneous Electrical Nerve Stimulation device for migraine treatment. Cefaly is a plastic headband, which can be worn across the forehead.

According to the report, a key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. The occurrence of side effects is the major reason that limits the use of migraine drugs. Moreover, there are still high levels of unmet need existing in certain niche populations, especially in patients who do not respond satisfactorily to triptans or patients for whom triptans are contraindicated.

Further, the report states that a challenge that could have a big impact on market growth is the lack of proper diagnosis of migraines.

Key vendors:

  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by type of treatment

PART 09: Market segmentation by therapeutic class

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/znnq8r/global_migraine

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com